Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Studies link gene with meningococcal septic shock:

This article was originally published in Clinica

Executive Summary

Two Dutch teams have discovered a genetic variation that could make a patient infected with the bacterium Neisseria meningitidis more susceptible to developing potentially-fatal septic shock. In the first study, researchers found that infected patients from families carrying a 4G/4G polymorphism in a gene which codes for plasminogen-activator-inhibitor (PAI-1), an enzyme involved in the formation of blood clots, were six times more likely to develop septic shock than meningitis. The second study showed that children with meningococcal disease who had the 4G/4G PAI-1 genotype had higher PAI-1 concentrations and an increased risk of death. Both studies appear in The Lancet (August 14).

You may also be interested in...



Latest UK COVID-19 Specification: For Rapidly Manufactured CPAP Systems

Following hot on the heels of its Rapidly Manufactured Ventilator Specification document, the UK’s regulator has issued another speedy regulatory permit for fast production of respiratory assist devices.

Podcast: Biopharma's Moment To Deliver On Coronavirus And The People's Hope

Which drug candidates represent hope, and which hype? The Scrip team examine the COVID-19 pipeline, lessons from China, and some long term impacts on the sector.

Hengrui Quickly Fills Celgene Void Amid Nationalism Surge In China

China insists there is no double standard and won’t tolerate any quality issues in its centralized procurement process.

Topics

UsernamePublicRestriction

Register

MT079251

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel